Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Active not recruiting 1

Sponsor Class

NIH 1

Study Type

Interventional 1

Sponsor

Cancer Type

Gastrointestinal 1CNS 1

Conditions

Turcot syndrome 1Medulloblastoma 1Glioma 1Familial ependymoma 1Ependymoma 1Diffuse Intrinsic Pontine Glioma 1Colorectal Neoplasms, Hereditary Nonpolyposis 1Brain Neoplasms 1

Interventions

Magnetic Resonance Spectroscopy 9Specimen Handling 7X-Rays 6Phantoms, Imaging 6Nuclear Medicine Department, Hospital 5Temozolomide 4Biopsy 4Vincristine 3Cyclophosphamide 3Cisplatin 3ulixertinib 2tipifarnib 2tazemetostat 2selpercatinib 2pembrolizumab 2palbociclib 2olaparib 2lutetium Lu 177 dotatate 2larotrectinib 2ivosidenib 2erdafitinib 2ensartinib 2Radiotherapy 2Radiation 2Platinum 2Lomustine 2LY3023414 2Diphtheria-Tetanus Vaccine 21,2-diaminocyclohexaneplatinum II citrate 2sodium thiosulfate 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Medulloblastoma × Diffusion Tensor Imaging × 90 days × Clear all
NCT02359565 2026-05-13

Pembrolizumab in Treating Younger Patients With Recurrent, Progressive, or Refractory High-Grade Gliomas, Diffuse Intrinsic Pontine Gliomas, Hypermutated Brain Tumors, Ependymoma or Medulloblastoma

National Cancer Institute (NCI)

Phase 1 Active not recruiting
71 enrolled
CNSGastrointestinal

Familial ependymoma, Turcot syndrome, Diffuse Intrinsic Pontine Glioma, Brain Neoplasms, Colorectal Neoplasms, Hereditary Nonpolyposis, Ependymoma, Glioma, Medulloblastoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡